Acadia Pharmaceuticals Stock Analysis

ACAD Stock  USD 17.44  0.51  3.01%   
ACADIA Pharmaceuticals is undervalued with Real Value of 21.0 and Target Price of 24.37. The main objective of ACADIA Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what ACADIA Pharmaceuticals is worth, separate from its market price. There are two main types of ACADIA Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The ACADIA Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and ACADIA Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.

ACADIA Stock Analysis Notes

About 99.0% of the company shares are held by institutions such as insurance companies. The book value of ACADIA Pharmaceuticals was presently reported as 4.4. The company last dividend was issued on the 30th of June 2010. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California. Acadia Pharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 540 people. For more info on ACADIA Pharmaceuticals please contact Stephen JD at 858 558 2871 or go to https://www.acadia.com.

ACADIA Pharmaceuticals Quarterly Total Revenue

244.32 Million

ACADIA Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. ACADIA Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding ACADIA Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
ACADIA Pharmaceuticals generated a negative expected return over the last 90 days
ACADIA Pharmaceuticals has high historical volatility and very poor performance
ACADIA Pharmaceuticals has a strong financial position based on the latest SEC filings
Over 99.0% of the company shares are held by institutions such as insurance companies
Latest headline from simplywall.st: ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations Heres What Analysts Think Will Happen Next

ACADIA Pharmaceuticals Upcoming and Recent Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

ACADIA Largest EPS Surprises

Earnings surprises can significantly impact ACADIA Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-08-06
2024-06-300.180.20.0211 
2022-11-02
2022-09-30-0.19-0.170.0210 
2013-08-06
2013-06-30-0.09-0.11-0.0222 
View All Earnings Estimates

ACADIA Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

ACADIA Pharmaceuticals' ESG score is a quantitative measure that evaluates ACADIA Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of ACADIA Pharmaceuticals' operations that may have significant financial implications and affect ACADIA Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.

ACADIA Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Fred Alger Management, Llc2024-12-31
2.7 M
First Trust Advisors L.p.2024-12-31
2.7 M
Point72 Asset Management, L.p.2024-12-31
2.2 M
Citigroup Inc2024-12-31
1.7 M
Tang Capital Management Llc2024-12-31
1.5 M
Norges Bank2024-12-31
1.4 M
Nuveen Asset Management, Llc2024-12-31
1.3 M
Two Sigma Advisers, Llc2024-12-31
1.3 M
Charles Schwab Investment Management Inc2024-12-31
1.3 M
Baker Bros Advisors Lp2024-12-31
42.9 M
Vanguard Group Inc2024-12-31
13.9 M
Note, although ACADIA Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

ACADIA Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.91 B.

ACADIA Profitablity

The company has Profit Margin (PM) of 0.24 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.03 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.03.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.21  0.22 
Return On Capital Employed 0.29  0.31 
Return On Assets 0.19  0.20 
Return On Equity 0.31  0.32 

Management Efficiency

ACADIA Pharmaceuticals has return on total asset (ROA) of 0.0544 % which means that it generated a profit of $0.0544 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3889 %, meaning that it created $0.3889 on every $100 dollars invested by stockholders. ACADIA Pharmaceuticals' management efficiency ratios could be used to measure how well ACADIA Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.22. The current year's Return On Capital Employed is expected to grow to 0.31. At present, ACADIA Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 82.8 M, whereas Net Tangible Assets are forecasted to decline to about 403.1 M.
Last ReportedProjected for Next Year
Book Value Per Share 4.42  4.64 
Tangible Book Value Per Share 3.70  3.88 
Enterprise Value Over EBITDA 27.69  29.07 
Price Book Value Ratio 4.15  4.46 
Enterprise Value Multiple 27.69  29.07 
Price Fair Value 4.15  4.46 
Enterprise Value1.7 B1.8 B
Evaluating the management effectiveness of ACADIA Pharmaceuticals allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The ACADIA Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Operating Margin
0.0269
Profit Margin
0.2364
Beta
0.475
Return On Assets
0.0544
Return On Equity
0.3889

Technical Drivers

As of the 12th of May 2025, ACADIA Pharmaceuticals owns the market risk adjusted performance of (0.14), and Variance of 9.51. ACADIA Pharmaceuticals technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the entity's future prices. Please confirm ACADIA Pharmaceuticals information ratio, potential upside, and the relationship between the standard deviation and maximum drawdown to decide if ACADIA Pharmaceuticals is priced adequately, providing market reflects its prevailing price of 17.44 per share. Given that ACADIA Pharmaceuticals has information ratio of (0.01), we suggest you to validate ACADIA Pharmaceuticals's latest market performance to make sure the company can sustain itself at some future date.

ACADIA Pharmaceuticals Price Movement Analysis

The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Triangular Moving Average shows ACADIA Pharmaceuticals double smoothed mean price over a specified number of previous prices (i.e., averaged twice).

ACADIA Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ACADIA Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on ACADIA Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ACADIA Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
James Kihara over a month ago
Disposition of 2010 shares by James Kihara of ACADIA Pharmaceuticals subject to Rule 16b-3
 
Mark Schneyer over a month ago
Disposition of 3171 shares by Mark Schneyer of ACADIA Pharmaceuticals at 17.05 subject to Rule 16b-3
 
Owen Adams Catherine over a month ago
Acquisition by Owen Adams Catherine of 940 shares of ACADIA Pharmaceuticals subject to Rule 16b-3
 
Mark Schneyer over two months ago
Disposition of 773 shares by Mark Schneyer of ACADIA Pharmaceuticals at 19.96 subject to Rule 16b-3
 
Mark Schneyer over two months ago
Disposition of 1353 shares by Mark Schneyer of ACADIA Pharmaceuticals subject to Rule 16b-3
 
Davis Stephen over three months ago
Disposition of 31747 shares by Davis Stephen of ACADIA Pharmaceuticals at 15.28 subject to Rule 16b-3
 
Brendan Teehan over three months ago
Disposition of 9913 shares by Brendan Teehan of ACADIA Pharmaceuticals subject to Rule 16b-3
 
Mark Schneyer over three months ago
Disposition of 9913 shares by Mark Schneyer of ACADIA Pharmaceuticals subject to Rule 16b-3
 
Ndu Adora over six months ago
Disposition of 4381 shares by Ndu Adora of ACADIA Pharmaceuticals subject to Rule 16b-3
 
Brendan Teehan over six months ago
Acquisition by Brendan Teehan of 1107 shares of ACADIA Pharmaceuticals subject to Rule 16b-3
 
Mark Schneyer over six months ago
Acquisition by Mark Schneyer of 13629 shares of ACADIA Pharmaceuticals subject to Rule 16b-3
 
Davis Stephen over six months ago
Disposition of 31747 shares by Davis Stephen of ACADIA Pharmaceuticals at 15.28 subject to Rule 16b-3

ACADIA Pharmaceuticals Outstanding Bonds

ACADIA Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ACADIA Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ACADIA bonds can be classified according to their maturity, which is the date when ACADIA Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

ACADIA Pharmaceuticals Predictive Daily Indicators

ACADIA Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ACADIA Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

ACADIA Pharmaceuticals Corporate Filings

9th of May 2025
Other Reports
ViewVerify
10Q
8th of May 2025
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
8K
7th of May 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
2nd of May 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
25th of April 2025
Other Reports
ViewVerify
8K
16th of April 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
8th of April 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
26th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify

ACADIA Pharmaceuticals Forecast Models

ACADIA Pharmaceuticals' time-series forecasting models are one of many ACADIA Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ACADIA Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About ACADIA Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how ACADIA Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ACADIA shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ACADIA Pharmaceuticals. By using and applying ACADIA Stock analysis, traders can create a robust methodology for identifying ACADIA entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin 0.27  0.28 
Operating Profit Margin 0.24  0.25 
Net Profit Margin 0.24  0.25 
Gross Profit Margin 0.91  0.96 

Current ACADIA Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ACADIA analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ACADIA analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
24.37Buy20Odds
ACADIA Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most ACADIA analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand ACADIA stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of ACADIA Pharmaceuticals, talking to its executives and customers, or listening to ACADIA conference calls.
ACADIA Analyst Advice Details

ACADIA Stock Analysis Indicators

ACADIA Pharmaceuticals stock analysis indicators help investors evaluate how ACADIA Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ACADIA Pharmaceuticals shares will generate the highest return on investment. By understating and applying ACADIA Pharmaceuticals stock analysis, traders can identify ACADIA Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow194.4 M
Common Stock Shares Outstanding166.4 M
Total Stockholder Equity732.8 M
Tax Provision31.6 M
Quarterly Earnings Growth Y O Y2.133
Property Plant And Equipment Net50.8 M
Cash And Short Term Investments756 M
Cash319.6 M
Accounts Payable16.2 M
Net Debt-267.6 M
50 Day M A16.1508
Total Current Liabilities394.9 M
Other Operating Expenses873.5 M
Non Current Assets Total249.4 M
Forward Price Earnings34.6021
Non Currrent Assets Other78.9 M
Stock Based Compensation67 M

Complementary Tools for ACADIA Stock analysis

When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Global Correlations
Find global opportunities by holding instruments from different markets